

REMARKS

Currently claims 1-20 are pending. Claims 14-20 are cancelled as being inappropriate to US practice. Accordingly, claims 1-13 are presented for examination. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,



John L. Lemanowicz
Attorney for Applicant
Registration No. 37,380

Date: 20 Jan 2005
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8247
Facsimile: 919-483-7988

ABSTRACT

The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds.